Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Convalescent Plasma for Severe COVID-19 Pneumonia
NCT04397757Phase 1Completed
- Sponsor
- University of Pennsylvania
- Start
- May 2020
- Primary completion
- Feb 2021
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial in COVID-19 pneumonia comparing Convalescent Plasma + SOC with Standard of Care (2 arms). Primary endpoints: Participants With Serious Adverse Events and Clinical Severity Score. Started May 2020; status: completed.
02
Drugs
COVID-19 convalescent plasma
03
Conditions
COVID-19 pneumonia
Beyond the preview
Go deeper on NCT04397757.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04397757.